CoChat

Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study

Open access
Dong, Jennifer Q., Rossulek, Michelle, Somayaji, Veena R., Baltrukonis, Daniel, Liang, Yali, Hudson, Krischan, Hernandez‐Illas, Martha, Calle, Roberto A. · 2015 · British Journal of Clinical Pharmacology
Cited by 100

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: The aim of the present study was to evaluate the pharmacokinetics/pharmacodynamics (PK/PD), safety and tolerability of single intravenous (IV) doses of PF‐05231023, a long acting fibroblast growth factor 21 (FGF21) analogue being developed for the treatment of type 2 diabetes mellitus (T2DM). Methods: T2DM subjects (glycosylated haemoglobin: 7.0–10.5%; on stable metformin therapy and/or diet and exercise) were randomized to receive a single dose of placebo or PF‐05231023 (0.5–200 mg). Safety evaluations were performed up to 14 days after dosing. PK and PD endpoints were measured and a PK/PD model was developed for triglyceride – an early marker of drug activity. Results: No antidrug antibody or serious adverse events (AEs) were observed. The most frequent AEs were gastrointestinal but were generally mild. Plasma PF‐05231023 levels peaked immediately post‐IV dosing, with mean terminal half‐lives of 6.5–7.7 h and 66.5– 96.6 h for intact C‐ and N‐termini, respectively. Intact C‐terminus exposures increased proportionally with increasing dose, whereas N‐terminus exposures appeared to trend higher than dose‐proportionally. Although no apparent effect on plasma glucose was seen, dose‐dependent decreases in triglyceride were observed, with a maximum reduction of 48.5 ± 10.0% (mean ± standard deviation) for the 200 mg dose compared with a reduction of 19.1 ± 26.4% for placebo, demonstrating proof of pharmacology. Moreover, a reduction in total cholesterol and low‐density lipoprotein cholesterol and an increase in high‐density lipoprotein cholesterol were observed in the high‐dose groups. Conclusions: Single IV doses of PF‐05231023 up to 200 mg were generally safe and well tolerated by subjects with T2DM. The observed early sign of pharmacology supports further clinical testing of PF‐05231023 upon repeated administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12676

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 100

Metadata

Authors
Dong, J. Q., Rossulek, M., Somayaji, V. R., Baltrukonis, D., Liang, Y., Hudson, K., Hernandez‐Illas, M., & Calle, R. A.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2015-07-29
Volume
80
Issue
5
Pages
1051-1063
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1522113235
Cited by
100
References
9
FWCI
5.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.